恶性淋巴瘤的综合治疗石远凯 ppt课件.ppt

Optimum Chemotherapy for Favorable StageⅠ - Ⅱ HL Regimens No. of pts outcome 5-year DFS 5-year OS A: VBM x 6 35 88% 94% +regional RT(36Gy) B: STLI(s)/TLI(s) 43 93% 98% (30-40Gy, boost 40-44Gy) P=0.60 P= 0.56 Eligibility :CS ⅠA - ⅡA or CS ⅠB - ⅡB with only night sweats without large mediastinal disease(1/3 maximum thoracic diameter) or ≥2 extranodal sites of disease Stanford Randomized Clinical Trial Horning SJ,et al. JCO.15:1736;1997 Optimum Chemotherapy for Favorable StageⅠ - ⅡHL Regimens No. of pts outcome 6-y EFS 6-y RRS 6-y OS A: EBVPx6+IFRT(36Gy) 168 90% 92% 98% B: STLI(S) 166 81% 81% 96% P= 0.50 P=0.004 P=0.156 Eligibility: CS ⅠA - ⅡB without age50 ESR ≥ 50mm in A; ≥ 30mm in B ≥ 4 sites of disease large mediastinal disease (≥ 0.35 maximum/thoracic ratio) CS ⅠA , NS/LP, age40, ESR50mm EORTC Randomized Clinical Trial Carde P, et al. PASCO 1997,P.13a Optimum Chemotherapy for Favorable Stage Ⅰ - Ⅱ HL Regimens No. of pts outcome FU F